Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference ...

On Thursday, RBC Capital analysts maintained an Outperform rating on Edgewise Therapeutics stock, with a price target of $48.00, representing significant upside from the current price of $14.27.

Edgewise Therapeutics, Inc. Supernus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. Liquidia Corporation Sector Health Care Health Care Health Care Health Care Health Care Health Care Industry ...

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a ...

Another element that sets digital therapeutics apart was outlined by Ben Lewis, CEO of Limbix, a developer of prescription digital therapeutics, who told pharmaphorum that the company has a ...

Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals. Ben ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...